Media Case StudiesMedia Development Case Studies

In a biosimilar project, during process development the target protein showedoxidation and truncation, showing considerable quality differences from the reference drug. Zencore performed custom media development and, combined with upstream and purification process development,bringing product quality in line with the reference drug。

In a biosimilar project undertaken by Zencore, custom media development brought the biosimilar'sGlycan profile highly similar to the reference drug. The project receivedApproved by the US FDA and proceeding directly into Phase III。

For a client's novel monoclonal antibody project, Zencore developed a high-yield media combination that, under a fed-batch culture process, achieved an antibody titer of 9.6 g/L, compared with mainstream commercial media, the cell culture process characteristics showeven better performance。

Zencore offers a range of platform media formulations with markedly different nutrient profiles, covering the nutritional types and culture characteristics of the vast majority of recombinant CHO cells. Together with Zencore'sHigh-throughput culture platform, the optimal medium for the recombinant cells can be identified during early clone evaluation while achieving high protein titers, greatly improving the robustness of clone screening and process development. The chart on the right listsFour different cell linesthe optimal medium and its culture characteristics at the clone evaluation stage, involvingThree Zencore-developed media sets, with protein titer at 7.1–10.5 g/L。